PMID: 2498455Apr 1, 1989Paper

Rise of plasma t-PA fibrinolytic activity in a group of maturity onset diabetic patients shifted from a first generation (tolbutamide) to a second generation sulphonylurea (gliclazide)

Journal of Internal Medicine
J GramJ Jespersen

Abstract

During treatment with tolbutamide 10 maturity onset diabetic patients had no detectable activity of tissue-type plasminogen activator (t-PA) determined on two occasions 3 months apart. All 10 patients responded on the change in treatment to gliclazide with an increase in activity of t-PA. However, after 12 months of treatment the t-PA activity in one of the 10 patients returned to the baseline level, whereas the remaining nine patients had a sustained increased t-PA activity compared to the period during treatment with tolbutamide. The concentration in plasma of t-PA antigen under basal conditions and after stimulation (venous occlusion) increased significantly during the period of treatment with gliclazide. The plasma concentrations of plasminogen activator inhibitor remained unchanged throughout the study. In contrast to these findings seven patients with marked activities of t-PA during treatment with tolbutamide retained unchanged levels of the variables reported above after a change in treatment to gliclazide. Serum glucose, HBA1c, apolipoproteins A and B, and triglycerides remained constant throughout the study, whereas serum cholesterol showed a decrease in both groups of patients after 3 months (P less than 0.05) as wel...Continue Reading

References

May 1, 1986·Scandinavian Journal of Clinical and Laboratory Investigation·J Hjelm Poulsen, J Jespersen
Jan 1, 1988·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·J AuwerxJ Geboers
Feb 1, 1988·Metabolism: Clinical and Experimental·M W Stolar
Nov 30, 1983·The American Journal of Medicine·J A ColwellP V Halushka

❮ Previous
Next ❯

Citations

Jan 1, 1991·Diabetes Research and Clinical Practice·D B CampbellC Nathan
Jan 1, 1991·Diabetes Research and Clinical Practice·O Ziegler, P Drouin
Oct 1, 1994·Journal of Diabetes and Its Complications·O Ziegler, P Drouin
Jan 1, 1991·Diabetes Research and Clinical Practice·J Duhault, R Lavielle
Jan 1, 1991·Diabetes Research and Clinical Practice·L P Krall
Jun 28, 2001·Journal of Atherosclerosis and Thrombosis·H NomuraA Iguchi
May 1, 1992·Metabolism: Clinical and Experimental·D N Brindley
May 1, 1992·Metabolism: Clinical and Experimental·J Gram, J Jespersen
May 1, 1992·Metabolism: Clinical and Experimental·K G AlbertiR Taylor

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.